Oyster Point Pharma, Inc.
OYSTNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for OYST. That does not mean none is planned.
Get an email about OYST's next catalysts
Track Oyster Point Pharma (OYST) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 0 past
No catalysts found.
Market Overview
Stock performance and key metrics
Varenicline Tartrate Nasal Spray
Dry Eye Disease
OC-01 (varenicline) nasal spray
Dry Eye Disease (DED)
OC-01 Mid
Long Term Follow up Dry Eye Disease
OC-01 High
Long Term Follow up Dry Eye Disease
OC-01 Low
Long Term Follow up Dry Eye Disease
OC-02 (simpinicline) nasal spray
Dry Eye Disease
hemigalactarate (free base) OC-02 High
Dry Eye Disease
OC-01 (varenicline) nasal
Neurotrophic Keratopathy
OC-01
Dry Eye Disease
hemigalactarate (free base) OC-02 Low
Dry Eye Disease
hemigalactarate (free base) OC-02 Mid
Dry Eye Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Varenicline Tartrate Nasal Spray | Phase 3 | Dry Eye Disease | - | - |
OC-01 (varenicline) nasal spray | Phase 3 | Dry Eye Disease (DED) | - | - |
OC-01 Mid | Phase 3 | Long Term Follow up Dry Eye Disease | - | - |
OC-01 High | Phase 3 | Long Term Follow up Dry Eye Disease | - | - |
OC-01 Low | Phase 3 | Long Term Follow up Dry Eye Disease | - | - |
OC-02 (simpinicline) nasal spray | Phase 2 | Dry Eye Disease | - | - |
hemigalactarate (free base) OC-02 High | Phase 2 | Dry Eye Disease | - | - |
OC-01 (varenicline) nasal | Phase 2 | Neurotrophic Keratopathy | - | - |
OC-01 | Phase 2 | Dry Eye Disease | - | - |
hemigalactarate (free base) OC-02 Low | Phase 2 | Dry Eye Disease | - | - |
hemigalactarate (free base) OC-02 Mid | Phase 2 | Dry Eye Disease | - | - |
Frequently asked questions
What is in Oyster Point Pharma, Inc.'s drug pipeline?β
CatalystAlert tracks 11 drug candidates in Oyster Point Pharma, Inc.'s (OYST) pipeline across Phase 3, Phase 2. Its lead program is OC-01 (varenicline) nasal spray (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Oyster Point Pharma, Inc.'s next FDA catalyst?β
CatalystAlert tracks every upcoming catalyst for Oyster Point Pharma, Inc. (OYST) β PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings β each confidence-rated as confirmed, estimated or AI-detected.
How do I track OYST biotech catalysts?β
Add OYST to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Oyster Point Pharma, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
